Abstract:Cytosolic sulfotransferase (SULT2B1b) catalyzes oxysterol sulfation. 5-Cholesten-3β-25-diol-3-sulfate (25HC3S), one product of this reaction, decreases intracellular lipids in vitro by suppressing liver X receptor/sterol regulatory element binding protein (SREBP)–1c signaling, with regulatory properties opposite to those of its precursor 25-hydroxycholesterol. Upregulation of SULT2B1b may be an effective strategy to treat hyperlipidemia and hepatic steatosis. The objective of the study was to explore the effect and mechanism of oxysterol sulfation by SULT2B1b on lipid metabolism in vivo. C57BL/6 and LDLR−/− mice were fed with high-cholesterol diet or high-fat diet for 10 weeks and infected with adenovirus encoding SULT2B1b. SULT2B1b expressions in different tissues were determined by immunohistochemistry and Western blot. Sulfated oxysterols in liver were analyzed by high-pressure liquid chromatography. Serum and hepatic lipid levels were determined by kit reagents and hematoxylin and eosin staining. Gene expressions were determined by real-time reverse transcriptase polymerase chain reaction and Western Blot. Following infection, SULT2B1b was successfully overexpressed in the liver, aorta, and lung tissues, but not in the heart or kidney. SULT2B1b overexpression, combined with administration of 25-hydroxycholesterol, significantly increased the formation of 25HC3S in liver tissue and significantly decreased serum and hepatic lipid levels, including triglycerides, total cholesterol, free cholesterol, and free fatty acids, as compared with controls in both C57BL/6 and LDLR−/− mice. Gene expression analysis showed that increases in SULT2B1b expression were accompanied by reduction in key regulators and enzymes involved in lipid metabolism, including liver X receptor α, SREBP-1, SREBP-2, acetyl-CoA carboxylase–1, and fatty acid synthase. These findings support the hypothesis that 25HC3S is an important endogenous regulator of lipid biosynthesis.

siRNA/CS‐PLGA Nanoparticle System Targeting Knockdown Intestinal SOAT2 Reduced Intestinal Lipid Uptake and Alleviated Obesity

siRNA/CS‐PLGA Nanoparticle System Targeting Knockdown Intestinal SOAT2 Reduced Intestinal Lipid Uptake and Alleviated Obesity (Adv. Sci. 40/2024)

Prevention of Obesity in Mice by Antisense Oligonucleotide Inhibitors of Stearoyl-Coa Desaturase-1.

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

SOAT1 regulates cholesterol metabolism to induce EMT in hepatocellular carcinoma

Cholesterol Activates the Wnt/PCP-YAP Signaling in SOAT1-targeted Treatment of Colon Cancer.

Soat2 inhibitor avasimibe alleviates acute pancreatitis by suppressing acinar cell ferroptosis

CD36 and DGAT2 facilitate the lipid-lowering effect of chitooligosaccharides via fatty acid intake and triglyceride synthesis signaling.

Oxysterol Sulfation by Cytosolic Sulfotransferase Suppresses Liver X Receptor/sterol Regulatory Element Binding Protein-1C Signaling Pathway and Reduces Serum and Hepatic Lipids in Mouse Models of Nonalcoholic Fatty Liver Disease.

siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice

Identification of Soat1 As a Quantitative Trait Locus Gene on Mouse Chromosome 1 Contributing to Hyperlipidemia

Simultaneously Targeting SOAT1 and CPT1A Ameliorates Hepatocellular Carcinoma by Disrupting Lipid Homeostasis

High-affinity SOAT1 ligands remodeled cholesterol metabolism program to inhibit tumor growth

Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease

Oligochitosan-based Nanovesicles for Nonalcoholic Fatty Liver Disease Treatment Via the FXR/miR-34a/SIRT1 Regulatory Loop.

Intestinal stearoyl-coenzyme A desaturase-inhibition improves obesity-associated metabolic disorders

Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-Induced Hepatic Steatosis and Insulin Resistance.

Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models

CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction

Pharmacological inhibition or genetic ablation of soluble epoxide hydrolase attenuates obesity-induced nonalcoholic fatty liver disease

SOAT1 Promotes Gastric Cancer Lymph Node Metastasis Through Lipid Synthesis